000			02181 a2200613 4500
005			20250517140309.0
264		0	_c20170814
008			201708s 0 0 eng d
022			_a1872-7980
024	7		_a10.1016/j.canlet.2017.01.042 _2doi
040			_aNLM _beng _cNLM
100	1		_aDilly, Suzanne J
245	0	0	_aA chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment. _h[electronic resource]
260			_bCancer letters _c05 2017
300			_a16-21 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_a17-Hydroxysteroid Dehydrogenases _xantagonists & inhibitors
650	0	4	_a3-Hydroxyacyl CoA Dehydrogenases _xantagonists & inhibitors
650	0	4	_aAdenocarcinoma _xdrug therapy
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xchemistry
650	0	4	_aAntipsychotic Agents _xchemistry
650	0	4	_aBacteriophage T7 _xgenetics
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrosophila melanogaster _xdrug effects
650	0	4	_aDrug Compounding
650	0	4	_aDrug Repositioning _xmethods
650	0	4	_aEnzyme Inhibitors _xchemistry
650	0	4	_aGene Library
650	0	4	_aGenomics _xmethods
650	0	4	_aHumans
650	0	4	_aLinoleic Acids, Conjugated _xchemistry
650	0	4	_aMale
650	0	4	_aMice, Nude
650	0	4	_aMolecular Docking Simulation
650	0	4	_aMolecular Targeted Therapy
650	0	4	_aProstatic Neoplasms _xdrug therapy
650	0	4	_aProtein Conformation
650	0	4	_aRisperidone _xchemistry
650	0	4	_aStructure-Activity Relationship
650	0	4	_aTime Factors
650	0	4	_aTumor Burden _xdrug effects
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aClark, Andrew J
700	1		_aMarsh, Andrew
700	1		_aMitchell, Daniel A
700	1		_aCain, Ricky
700	1		_aFishwick, Colin W G
700	1		_aTaylor, Paul C
773	0		_tCancer letters _gvol. 393 _gp. 16-21
856	4	0	_uhttps://doi.org/10.1016/j.canlet.2017.01.042 _zAvailable from publisher's website
999			_c26871815 _d26871815